Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in October
– Cantor Global Healthcare Conference presentation with live audio webcast on Monday, October 1st at 2:55 PM ET –
– Leerink Partners Roundtable Series: Rare Disease & Oncology fireside chat and live audio webcast on Tuesday, October 2nd at 3:00 PM ET –
Norwood, MA , Sept. 26, 2018 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases by leveraging its industry leading pipeline of endocannabinoid system-targeting drug candidates, announced today that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present at two upcoming investor conferences in October.
The following are the details for the conferences:
Event: Cantor Global Healthcare Conference
Date: Monday, October 1, 2018
Time: 2:55 p.m. Eastern Time
Location: InterContinental New York Barclay Hotel, New York, NY
Event: Leerink Partners Roundtable Series: Rare Disease & Oncology
Date: Tuesday, October 2, 2018
Time: 3:00 p.m. Eastern Time
Location: Lotte New York Palace, New York, NY
As part of his presentation, Dr. Cohen will provide a corporate overview including the Company’s recently announced transaction, the licensing of exclusive worldwide rights to develop, manufacture and market drug candidates from more than 600 compounds targeting the endocannabinoid system from Jenrin Discovery LLC. This pipeline includes candidate CRB-4001, a CB1 inverse agonist that is scheduled to enter a Phase 1 study in 2019 followed by a NIH-supported Phase 2 study.
Dr. Cohen will also discuss in detail the Company's four clinical development programs in diffuse cutaneous systemic sclerosis ("SSc"), cystic fibrosis ("CF"), dermatomyositis ("DM") and systemic lupus erythematosus ("SLE") for lenabasum, its novel, synthetic oral endocannabinoid-mimetic drug that is designed to resolve chronic inflammation and halt fibrosis.
Corbus' RESOLVE-1 study, a multicenter, randomized, double-blind Phase 3 study in SSc of lenabasum and its Phase 2 study of lenabasum for the treatment of SLE are currently underway. Additionally, patient enrollment and dosing are ongoing in its Phase 2b multicenter, double-blinded, randomized, placebo-controlled study of lenabasum for the treatment of CF. The CF study will enroll approximately 415 patients with CF who are at least 12 years of age and at increased risk for pulmonary exacerbations. In support of the Phase 2b study, Corbus received a Development Award for up to $25 million from the Cystic Fibrosis Foundation. The Company recently announced its plans to initiate its international Phase 3 study in approximately 150 adults with DM before year end. The Phase 3 DM study will be a 1-year, double-blind, randomized, placebo-controlled study testing efficacy and safety of lenabasum.
Live audio webcast of both the presentations will be accessible on the Events page of the Investors section of Corbus website, www.corbuspharma.com, and will be archived on the Company’s website for 90 days following the event.
About Lenabasum
Lenabasum (formerly known as anabasum) is a synthetic, oral, small-molecule, selective cannabinoid receptor type 2 (CB2) agonist that has been shown to preferentially bind to CB2 expressed on activated immune cells and fibroblasts in animal studies. CB2 activation triggers physiologic pathways that resolve inflammation, speed bacterial clearance and halt fibrosis. CB2 activation also induces the production of specialized pro-resolving lipid mediators that activate an endogenous cascade responsible for the resolution of inflammation and fibrosis, while reducing production of multiple inflammatory mediators. Through activation of CB2, lenabasum also is believed to have a direct effect on fibroblasts to halt tissue scarring. In preclinical and clinical studies conducted so far, lenabasum has been shown to induce resolution rather than immunosuppression by triggering biological pathways to turn "off" chronic inflammation and fibrotic processes. Lenabasum has demonstrated promising potency in preclinical models of inflammation and fibrosis. Preclinical data and clinical studies to date have shown lenabasum to have a favorable safety, tolerability and pharmacokinetic profile. Data to date suggest that the drug may have clinical benefit as well as a beneficial impact on inflammatory and immunological markers in Phase 2 studies in diffuse cutaneous systemic sclerosis, dermatomyositis and cystic fibrosis. Additional clinical studies are being conducted and/or planned to confirm these preliminary results and support applications for regulatory approval.
About Corbus
Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases by leveraging its industry leading pipeline of endocannabinoid system-targeting drug candidates. The Company's lead product candidate, lenabasum, is a novel, synthetic, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.
Corbus licensed the exclusive worldwide rights to develop, manufacture and market drug candidates from more than 600 compounds targeting the endocannabinoid system from Jenrin Discovery LLC. The pipeline includes CRB-4001, a 2nd generation, peripherally-restricted, selective cannabinoid receptor type 1 (CB1) inverse agonist specifically designed to eliminate blood-brain barrier penetration and brain CB1 receptor occupancy that mediate the neuropsychiatric issues associated with first-generation CB1 inverse agonists. Potential indications for CRB-4001 include NASH, primary biliary cholangitis, idiopathic pulmonary fibrosis, radiation-induced pulmonary fibrosis, myocardial fibrosis after myocardial infarction and acute interstitial nephritis, among others. CRB-4001 is scheduled to enter a Phase 1 study in 2019 followed a National Institutes of Health (NIH)-funded first-in-patient Phase 2 study.
For more information, please visit www.CorbusPharma.com and connect with the Company on Twitter, LinkedIn, and Facebook.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential, "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Source: Corbus Pharmaceuticals Holdings, Inc.
###
Investor Contacts: Institutional Investor Inquiries Ted Jenkins, Senior Director, Investor Relations and Communications Corbus Pharmaceuticals, Inc. Phone: +1 (617) 415-7745 Email: ir@corbuspharma.com All Other Investor Inquiries Jenene Thomas Jenene Thomas Communications, LLC Phone: +1 (833) 475-8247 Email: crbp@jtcir.com Media Contact Eliza Schleifstein Scient Public Relations Phone: + 1 (917) 763-8106 Email: eliza@scientpr.com
Released September 26, 2018